PTEN, a tumor suppressor and an antagonist of PI3K signaling, is another intermediate node in the network whose expression was significantly downregulated in PG+ tumors (Figure 6c,f; Figure S30, Supporting Information).[43] Interestingly, the only intermediate that did not show any change in PG+ patient tumors compared to healthy tissues was EGFR (Figure 6f; Figure S30, Supporting Information), supporting our experimental data which revealed robustness of sulfation‐mediated growth and invasiveness against EGFR inhibition (Figure 3b–d). This evidence concerns the gene PIK3CA and neoplasm.